Comparative Pharmacology
Head-to-head clinical analysis: CHORIONIC GONADOTROPIN versus PREGNYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHORIONIC GONADOTROPIN versus PREGNYL.
CHORIONIC GONADOTROPIN vs PREGNYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chorionic gonadotropin (hCG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Human chorionic gonadotropin (hCG) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads, stimulating testosterone production in males and ovulation in females.
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
Intramuscular injection: 5,000-10,000 IU once weekly for 4-9 weeks for ovulation induction; 1,000-2,000 IU three times weekly for spermatogenesis.
None Documented
None Documented
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
Terminal elimination half-life: 23–24 hours; clinically, supports daily or every-other-day dosing; peak effect may lag due to prolonged absorption
Primarily renal; intact hCG is excreted in urine. Negligible biliary/fecal elimination.
Renal: 10-20% as unchanged drug; hepatic metabolism to inactive metabolites; fecal excretion negligible (<5%)
Category C
Category C
Gonadotropin Hormone
Gonadotropin Hormone